← Leaderboards
Christopher W Peterson
Fred Hutchinson Cancer Center
$4,927,751
Attributed
$6,034,940
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$6,034,940 · 3
By mechanism
R01$5,563,883 · 2
R21$471,057 · 1
Top collaborators
- Afamefuna Okoye2 shared
- Hamideh Parhiz2 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Ajay Gopal$4,782,402
- Dan H. Barouch$218,203,090
- Damian J. Green$13,222,447
- Hans-Peter Kiem$98,160,227
- Joshua Tisdell Schiffer$7,320,811
Others in their field
Other Rising Stars on “Dose”
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Suma Babu · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Dawn Fallacara · Battelle Centers/Pub Hlth Res & Evaluatn$13,673,728
Research focus
DoseCellsAntibodiesVirusAntigensIn VivoChimeric Antigen Receptor T CellsMacaca MulattaExperimental StudyNonhuman PrimateB-LymphocytesTechnologyInfectionClinical ResearchCrispr/Cas TechnologyTraffickingGene TherapyAnimalsHiv-1Disease RemissionAntiretroviral TherapyGenesMalignant NeoplasmsSuccess
Grant awards (10)
Developing Durable, Env-Boosted CAR T Cells for HIV Cure$814,373
R01 · FY2025 · AI · contact PI
In Vivo Gene Editing of B cells with NICE-AAV Vectors$730,441
R01 · FY2025 · AI · contact PI
Developing Durable, Env-Boosted CAR T Cells for HIV Cure$849,858
R01 · FY2024 · AI · contact PI
In Vivo Gene Editing of B cells with NICE-AAV Vectors$770,685
R01 · FY2024 · AI · contact PI
Developing Durable, Env-Boosted CAR T Cells for HIV Cure$893,464
R01 · FY2023 · AI · contact PI
In Vivo Gene Editing of B cells with NICE-AAV Vectors$771,804
R01 · FY2023 · AI · contact PI
Optimizing the Depletion of innate immune Effector Cells in Nonhuman Primates$205,403
R21 · FY2023 · AI
In Vivo Gene Editing of B cells with NICE-AAV Vectors$462,111
R01 · FY2022 · AI · contact PI
In Vivo Gene Editing of B cells with NICE-AAV Vectors$271,147
R01 · FY2022 · AI · contact PI
Optimizing the Depletion of innate immune Effector Cells in Nonhuman Primates$265,654
R21 · FY2022 · AI